SARS-CoV-2 en el adulto mayor con enfermedad neurodegenerativa

Johanna Lizeth  González Devia; Myriam Leonor  Torres Pérez; Diana María  Cuartas Méndez

doi:10.22490/24629448.4196

Vol. 18 No. 35 (2020)

Published 2020-09-25

license

Article (before OJS)

SARS-CoV-2 in older adult with neurodegenerative disease

DOI: https://doi.org/10.22490/24629448.4196

Johanna Lizeth González Devia Universidad Santo Tomás

Myriam Leonor Torres Pérez Universidad Nacional Abierta y Distancias

Diana María Cuartas Méndez Universidad Santo Tomás

PDF (Spanish)

Abstract
References

Despite the many neurological complications associated with SARS-CoV-2 infection, it isn´t still clear whether these symptoms are the result of direct neural injury or due to some other reason. Currently, it appears that most of the neurological symptoms of COVID-19 are nonspecific and secondary to systemic disease.

To date, there is not enough scientific evidence to confirm that SARS-CoV-2 virus directly affects the central or peripheral nervous system in humans. This short article presents the implications of SARS-CoV-2 in the elderly with neurodegenerative disease, as well as the related mechanisms of action in the nervous system.

keywords: Sars-CoV2, covid-19, nervous system, neurodegenerative disease, older adult

OMS. Brote de enfermedad por coronavirus (COVID-19) 2020 [cited 2020 15 de julio]. Available from: https://www.who.int/es/emergencies/diseases/novel-coronavirus-2019.

Das G, Mukherjee N, Ghosh S. Neurological Insights of COVID-19 Pandemic. ACS Chem Neurosci. 2020;11(9):1206-9.

Serrano-Castro PJ, Estivill-Torrús G, Cabezudo-García P, Reyes-Bueno JA, Ciano Petersen N, Aguilar-Castillo MJ, et al. Influencia de la infección SARS-CoV-2 sobre enfermedades neurodegenerativas y neuropsiquiátricas: ¿una pandemia demorada? Neurología. 2020;35(4):245-51.

Asad AS, Zuccato CF, Candia AJN, Gottardo MF, Ayala MAM, Theas MS, et al. Papel del péptido mitocondrial humanina como blanco terapéutico en cáncer y neurodegeneración. Nova. 2019;17(32):9-24.

Niazkar HR, Zibaee B, Nasimi A, Bahri N. The neurological manifestations of COVID-19: a review article. Neurol Sci. 2020:1-5.

Abboud H, Abboud FZ, Kharbouch H, Arkha Y, El Abbadi N, El Ouahabi A. COVID-19 and SARS-Cov-2 Infection: Pathophysiology and Clinical Effects on the Nervous System. World Neurosurg. 2020;140:49-53.

Hascup ER, Hascup KN. Does SARS-CoV-2 infection cause chronic neurological complications? Geroscience. 2020:1-5.

Boika AV. A Post-COVID-19 Parkinsonism in the Future? Mov Disord. 2020:10.1002/mds.28117.

Monteiro-Junior RS. COVID-19: Thinking about further mental and neurological disorders. Med Hypotheses. 2020;143:109894-.

Salari M, Zali A, Ashrafi F, Etemadifar M, Sharma S, Hajizadeh N, et al. Incidence of Anxiety in Parkinson's Disease During the Coronavirus Disease (COVID-19) Pandemic. Mov Disord. 2020:10.1002/mds.28116.

Singh AK, Bhushan B, Maurya A, Mishra G, Singh SK, Awasthi R. Novel coronavirus disease 2019 (COVID-19) and neurodegenerative disorders. Dermatol Ther. 2020:e13591-e.

Garg D, Dhamija RK. The Challenge of Managing Parkinson's Disease Patients during the COVID-19 Pandemic. Ann Indian Acad Neurol. 2020;23(Suppl 1):S24-S7.

Cheng Q, Yang Y, Gao J. Infectivity of human coronavirus in the brain. EBioMedicine. 2020;56:102799-.

Pereira A. Long-Term Neurological Threats of COVID-19: A Call to Update the Thinking About the Outcomes of the Coronavirus Pandemic. Front Neurol. 2020;11:308-.

Lippi A, Domingues R, Setz C, Outeiro TF, Krisko A. SARS-CoV-2: At the Crossroad Between Aging and Neurodegeneration. Mov Disord. 2020;35(5):716-20.

license

How to Cite

González Devia, J. L. ., Torres Pérez, M. L. ., & Cuartas Méndez, D. M. . (2020). SARS-CoV-2 in older adult with neurodegenerative disease. NOVA Biomedical Sciences Journal, 18(35), 121-127. https://doi.org/10.22490/24629448.4196

Download Citation

Almétricas

Metrics

File downloads

260

| |

Declaración de privacidad.

SARS-CoV-2 in older adult with neurodegenerative disease

Declaración de privacidad.